BCM
PMVP icon

BML Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

BML Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.6M Buy
5,320,000
+28,000
+0.5% +$35.6K 4.24% 6
2025
Q4 		$6.62M Hold
5,292,000
– – 5.72% 5
2025
Q3 		$7.41M Buy
5,292,000
+292,000
+6% +$404K 6.78% 6
2025
Q2 		$5.3M Buy
5,000,000
+1,252,388
+33% +$1.23M 4.01% 9
2025
Q1 		$4.08M Buy
3,747,612
+280,928
+8% +$381K 3.31% 10
2024
Q4 		$5.23M Buy
3,466,684
+1,777,912
+105% +$2.82M 3.25% 11
2024
Q3 		$2.52M Buy
1,688,772
+379,375
+29% +$586K 1.48% 14
2024
Q2 		$2.12M Buy
1,309,397
+2,907
+0.2% +$5.24K 1.51% 14
2024
Q1 		$2.22M Buy
+1,306,490
New +$2.44M 1.46% 15

Other funds holding PMVP

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BML Capital Management's PMVP Position: Q1 2026 in Review

BML Capital Management increased its PMV Pharmaceuticals (PMVP) stake by 0.53% in Q1 2026, buying an estimated $35.6K and bringing the position to 5,320,000 shares worth $6.6M. The position accounts for 4.24% of the portfolio, ranked #6.

BML Capital Management first reported a position in PMVP in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.41M in Q3 2025. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • BML Capital Management held 5,320,000 shares of PMV Pharmaceuticals worth $6.6M as of Q1 2026.
  • BML Capital Management bought 28,000 PMV Pharmaceuticals shares in Q1 2026, an estimated $35.6K.
  • PMV Pharmaceuticals made up 4.24% of BML Capital Management's portfolio in Q1 2026, its #6 holding.
  • BML Capital Management first reported a position in PMV Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • BML Capital Management's PMV Pharmaceuticals position peaked at $7.41M in Q3 2025.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on BML Capital Management's 13F filing for Q1 2026, filed 6 May 2026.